Products

Recombinant Human Interferon Alfa 2b Injection

Strength：

0.3ml: 3MIU, 0.5ml: 5MIU, 0.6ml: 6MIU

Indications and Dosage：

1. It is indicated for treatment of some viral diseases, such as acute and chronic viral hepatitis, herpes zoster and genital warts.
2. It can be used for treatment of some cancers, such as hairy cell leukemia, chronic myeloid leukemia, multiple myeloma, non-Hodgkin lymphoma, malignant melanoma, renal cell carcinoma, laryngeal papilloma, Sarcoma, ovarian cancer, basal cell carcinoma and superficial bladder .

Open

Put Away

Interferon Alfa-2b Vaginal Effervescent Tablet

Strength：

0.5 MIU

Indications and Dosage：

Ingredients

Main Components:

Recombinant Human Interferon α-2b.

Description：

White or off-white oval tablet.

Indication：

It is indicated for treatment of cervical erosion caused by viral infection and for prevention and treatment of HPV infection.

Administration and Dosage：

Place one tablet into the vaginal dome prior to sleep, once every other day. Nine doses consist of one course of treatment or under supervision of a physician.

Storage：

Store and transport at 2-8 ℃ and in a dry place protected from light.

Package：

Cold forming composite aluminum blister package. 3 tablets/box, or 9 tablets/box. Sterilized finger-bags or dosing devices are included in each unit of package.

 

Open

Put Away

Coblopasvir Hydrochloride Capsules

Strength: 60 mg

Indications:

This drug product is indicated for the treatment of HCV Genotypes 1, 2, 3 and 6 infections in naive adult patients or patients previously treated with interferons as used in combination with sofosbuvir, complicated by compensatory cirrhosis or not.

Dosage and Administration:

Orally take 60 mg with or without meals once a day for 12 consecutive weeks.

Orally take sofosbuvir 400 mg with or without meals concomitantly once a day for 12 consecutive weeks.

Pharmacology:

Coblopasvir hydrochloride is an inhibitor of HCV NS5A replication complex. NS5A is a phosphate protein that can interact with a variety of host cell proteins and exert functions in the replication and assembly stages of the HCV life cycle. Studies have shown that NS5A may interact with other HCV proteins or host cell factors to play its role. Coblopasvir hydrochloride has a strong inhibitory effect on HCV genotypes 1a, 1b, 2a, 3a, 4a, 5a and 6a.

Storage:

Store in the original carton not higher than 30°C.

Package:

Pack in aluminum-plastic blisters. 7 capsules/blister ×1 blister/box; 7 capsules/blister ×2 blisters/box; 7 capsules/plate ×3 blisters/box; 7 capsules/blister ×4 blisters/box; 7 capsules/blister ×8 blisters/box; 7 capsules/blister ×12 blisters/box; 10 capsules/blister ×1 blister /box; 10 capsules/blister ×2 blisters /box; 10 capsules/blister ×3 blisters /box;

Shelf life:

24 months

Open

Put Away

Sofosbuvir Tablets

Strength: 0.4g

Indications:

Sofosbuvir is indicated for the treatment of chronic Genotype 2 hepatitis C virus (HCV) in adults as used in combination with ribavirin.

Sofosbuvir in combination with Coblopasvir hydrochloride is indicated for the treatment of HCV Genotypes 1, 2, 3 and 6 infections, complicated by compensatory cirrhosis or not, in naive adult patients or patients previously treated with interferons.

Dosage and Administration:

The drug product is indicated in the adult patients with chronic Genotype 2 HCV infection.

The administration of the drug product should be prescribed and monitored by a physician with rich experience in the management of patients with chronic HCV infection.

The recommended dose is one tablet (0.4 g/tablet) daily, taken orally with food, for 12 consecutive weeks.

The drug product should be administered with ribavirin. It is not recommended to be administered alone. See the prescription information of the drug to be administered in combination with this drug product.

The dose of ribavirin should be adjusted based on weight (< 75kg = 1000 mg，≥ 75 kg = 1200 mg), and orally taken with food in twice as it is administered with sofosbuvir.

As the drug product is administered with coblopasvir hydrochloride, the dose is one tablet (0.4 g/tablet) daily, per os, for 12 consecutive weeks. It can be orally taken under fasting condition or with meals. Moreover, coblopasvir hydrochloride is orally taken under fasting condition or with meals once a day for 12 consecutive weeks.

Storage:

Store in the original carton below 30℃.

Package:

The drug product is supplied in aluminum-plastic blister, externally with a moisture barrier bag. 7 tablets/plate × 1 plate/box, 7 tablets/plate × 2 plates/box, 7 tablets/plate × 4 plates/box, and 10 tablets/plate × 3 plates/box.

Shelf Life:

24 months.

 

 

Open

Put Away

Peginterferon Alfacon-2 Injection

Strength：

0.15 mg/1.0ml/piece

Packing：

One-vial package is containing 0.15 mg per 1.0 mL solution. The vial is made of neutral borosilicate glass tubing plugged tightly with chlorobutyl rubber stopper coated with polytetrafluoroethylene / hexafluoropropylene.

Indications and Dosage：
It is indicated for the treatment of chronic hepatitis C (HCV) in adults without liver decompensation. Preferably used this product combined with ribavirin for chronic hepatitis C. Please refer to the prescribing information of ribavirin when undertake combined therapy. Monotherapy is indicated only if patient has contraindication or significant intolerance to ribavirin.

Open

Put Away